Clinical Lung Cancer
Clinical Lung Cancer is a specialist journal of lung cancer clinical research, founded in Dallas in August 1999 by the Cancer Information Group and now published by Elsevier, appearing bimonthly. It is oriented towards clinical usefulness and is a regular reading source for lung cancer specialists.《临床肺癌》（Clinical Lung Cancer）是一份聚焦肺癌临床研究的专科期刊，一九九九年八月由癌症信息集团创办于美国达拉斯，现由爱思唯尔（Elsevier）出版，双月刊发行。该刊以临床实用性为导向，是肺癌专科医师追踪诊疗进展的常用刊物。
Scope
Clinical Lung Cancer sets out to serve clinical decision-making, its official scope running from detection through diagnosis to treatment and excluding basic lung cancer biology with no clinical bearing. Its principal subject areas include:Clinical Lung Cancer 的取稿立场是「面向临床决策的肺癌研究」，官方范围说明从检测诊断到治疗逐段展开，不涉及肺癌基础生物学中与临床无关的部分。收文范围覆盖的主要方向包括：
- Detection and diagnosis: the detection, diagnosis and prevention of lung cancer, including clinical assessment of imaging and pathological diagnosis.检测与诊断： 肺癌的检测、诊断与预防，包括影像与病理诊断的临床评估。
- Clinical research methods: the design and mechanistic approaches of clinical research, together with pathology, markers and prognostic indicators.临床研究方法： 临床研究的设计与机制学方法，以及病理、标志物与预后指标。
- Drug sensitivity and resistance: drug sensitivity, acquired resistance mechanisms and counter-strategies.药物敏感与耐药： 药物敏感性、获得性耐药机制与应对策略。
- Novel therapies: clinical trials of gene therapy, antisense therapy and targeted therapy.新型治疗： 基因治疗、反义治疗与靶向治疗的临床试验。
- Chemoprevention and integrated therapy: chemoprevention strategies and models of multidisciplinary integrated treatment.化学预防与整合治疗： 化学预防策略与多学科整合治疗模式。
The journal carries original papers, invited reviews, current treatment reports, case reports and meeting reports. Elsevier's official 2025 figures give thirteen days from submission to first decision, including editorial desk review, sixty-seven days to a decision after review, one hundred and ten days to acceptance and five days from acceptance to online publication该刊收原创论文、特邀综述、当代治疗报告、病例报告与会议报道。二〇二五年爱思唯尔官方指标显示：投稿至首次决定十三天（含编辑部桌审）、复审后决定六十七天、投稿至录用一百一十天、录用至五天在线发表；出版方未公布录用率。 no acceptance rate is published.[1]
History
- Founding (1999): the journal was founded in August 1999 by the Cancer Information Group of Dallas, Texas, under its present title and without later renaming.创刊（一九九九年）： 本刊于一九九九年八月由美国达拉斯的癌症信息集团创办，创刊时刊名即为 Clinical Lung Cancer，无更名。[2]
- Publisher transition (2011): the founding group published successively as the Cancer Information Group and CIG Media Group, with Elsevier taking over publication from 2011 and continuing since出版方沿革（二〇一一年）： 创刊方先后以癌症信息集团与 CIG 媒体集团名义出版，二〇一一年起转由爱思唯尔出版并延续至今；本刊无学会背景。 the journal has no society affiliation.[2]
- Frequency evolution: the journal was a quarterly from August 1999 to May 2002 and bimonthly from July 2002刊期沿革： 一九九九年八月至二〇〇二年五月为季刊，二〇〇二年七月起改双月刊；近年各卷每年约八期，略高于纯双月刊节奏。 recent volumes have run to about eight issues a year, slightly above a pure bimonthly rhythm.[3]
- Metric standing: the 2025 impact factor is 3.9, placing the journal in the second quartile of oncology and zone three of medicine in the Chinese Academy of Sciences ranking.指标走势： 二〇二五年影响因子三点九，在肿瘤学小类列二区，在中科院医学大类列三区。[1]
Editors
The journal operates under an editor-in-chief with five senior associate editors, four associate editors and dedicated commissioning and social media editors, fifty editors and board members in all across eight countries, thirty-eight of them in the United States, a mid-sized editorial layer for a clinical oncology title.本刊实行主编统筹的编辑架构，配五名资深副编辑、四名副编辑及分管约稿与社交媒体的专职编辑，编委及编辑共五十人、分驻八国，美国占三十八人，是规模中等的临床肿瘤学刊物编委层。[4]
- Antoinette Wozniak (editor-in-chief): lung cancer clinical trial specialist at the UPMC Hillman Cancer Center in the United States, with more than thirty years in lung cancer clinical work and research and a founding member of the Free to Breathe foundation.安托瓦内特·沃兹尼亚克（现任主编）： 美国匹茨堡大学希尔曼癌症中心肺癌临床试验专家，从事肺癌临床与研究三十余年，为「自由呼吸」基金会创始成员。[4]
- David R. Gandara (immediate past editor): a lung cancer translational research specialist at the University of California, Davis, succeeded by Wozniak.大卫·甘达拉（前任主编）： 美国加州大学戴维斯分校肺癌转化研究专家，其后由沃兹尼亚克接任。[5]